Q3 EPS Estimate for Mineralys Therapeutics Raised by Analyst

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) – Stock analysts at HC Wainwright upped their Q3 2026 earnings estimates for Mineralys Therapeutics in a research report issued on Wednesday, August 12th. HC Wainwright analyst M. Caufield now forecasts that the company will post earnings of ($0.56) per share for the quarter, up from their prior forecast of ($0.61). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Mineralys Therapeutics’ current full-year earnings is ($2.30) per share. HC Wainwright also issued estimates for Mineralys Therapeutics’ Q4 2026 earnings at ($0.60) EPS, FY2026 earnings at ($4.47) EPS, FY2027 earnings at ($3.78) EPS, FY2028 earnings at ($2.27) EPS and FY2029 earnings at $0.42 EPS.

Other equities analysts have also issued research reports about the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Mineralys Therapeutics in a research note on Friday, July 17th. Jefferies Financial Group reiterated a “hold” rating on shares of Mineralys Therapeutics in a report on Monday, June 1st. TD Cowen started coverage on Mineralys Therapeutics in a research note on Monday, April 27th. They set a “buy” rating for the company. Finally, Wall Street Zen cut shares of Mineralys Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $49.33.

Mineralys Therapeutics Price Performance

Shares of MLYS stock opened at $26.09 on Friday. The company has a market capitalization of $2.31 billion, a PE ratio of -6.15 and a beta of 0.68. The firm’s 50-day moving average is $26.44 and its two-hundred day moving average is $27.55. Mineralys Therapeutics has a 12 month low of $13.40 and a 12 month high of $47.65.

Mineralys Therapeutics (NASDAQ:MLYS) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($2.85) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.55) by ($2.30).

Insider Buying and Selling at Mineralys Therapeutics

In other Mineralys Therapeutics news, insider David Malcom Rodman sold 2,170 shares of the firm’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $27.09, for a total transaction of $58,785.30. Following the completion of the transaction, the insider directly owned 51,384 shares in the company, valued at approximately $1,391,992.56. This trade represents a 4.05% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Jon Congleton sold 75,000 shares of Mineralys Therapeutics stock in a transaction dated Tuesday, June 30th. The stock was sold at an average price of $26.14, for a total transaction of $1,960,500.00. Following the transaction, the chief executive officer owned 614,321 shares of the company’s stock, valued at approximately $16,058,350.94. The trade was a 10.88% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 217,313 shares of company stock valued at $5,624,488 in the last quarter. Insiders own 18.94% of the company’s stock.

Hedge Funds Weigh In On Mineralys Therapeutics

Several hedge funds have recently bought and sold shares of the stock. Jennison Associates LLC boosted its stake in Mineralys Therapeutics by 234.4% in the 4th quarter. Jennison Associates LLC now owns 1,258,653 shares of the company’s stock worth $45,677,000 after buying an additional 882,307 shares during the last quarter. TimesSquare Capital Management LLC purchased a new position in Mineralys Therapeutics during the fourth quarter worth approximately $13,794,000. UBS Group AG grew its stake in shares of Mineralys Therapeutics by 124.9% during the 4th quarter. UBS Group AG now owns 201,280 shares of the company’s stock valued at $7,304,000 after buying an additional 111,776 shares during the period. Artia Global Partners LP raised its position in shares of Mineralys Therapeutics by 143.5% in the 4th quarter. Artia Global Partners LP now owns 137,800 shares of the company’s stock worth $5,001,000 after buying an additional 81,200 shares during the period. Finally, Profund Advisors LLC increased its stake in Mineralys Therapeutics by 548.1% during the fourth quarter. Profund Advisors LLC now owns 47,024 shares of the company’s stock worth $1,707,000 after acquiring an additional 39,768 shares during the last quarter. Hedge funds and other institutional investors own 84.46% of the company’s stock.

Key Headlines Impacting Mineralys Therapeutics

Here are the key news stories impacting Mineralys Therapeutics this week:

• Positive Sentiment: FDA decision and launch preparations remain on track: Mineralys reiterated a December 22, 2026 PDUFA date for lorundrostat, its investigational hypertension treatment, and said commercial launch preparations are progressing. Launch readiness and cash runway
• Positive Sentiment: Cash runway provides financial flexibility: Management said its cash position should fund operations into 2028, reducing near-term financing risk as the company advances toward a potential launch. The company also highlighted actions intended to improve lorundrostat’s long-term economics. Second-quarter earnings call highlights
• Positive Sentiment: Near-term EPS estimates improved: HC Wainwright raised its Q3 2026 EPS forecast to a loss of $0.56 from $0.61 and its Q4 forecast to a loss of $0.60 from $0.70, while retaining its Buy rating.
• Neutral Sentiment: New chief medical officer appointed: Mineralys granted Dr. Terry Ferguson inducement awards covering 135,000 stock options and 102,400 restricted stock units. The appointment strengthens late-stage development leadership, although the equity awards create potential dilution. Inducement award announcement
• Negative Sentiment: Large quarterly earnings miss: Mineralys reported a second-quarter loss of $2.85 per share, far worse than the $0.55 consensus loss, increasing concerns about spending and execution even though the company remains pre-commercial. Second-quarter earnings call transcript
• Negative Sentiment: Long-term earnings outlook was reduced: HC Wainwright cut its FY2026 EPS estimate to a $4.47 loss from $2.33, FY2027 to a $3.78 loss from $2.84, FY2028 to a $2.27 loss from $1.52, and FY2029 profit to $0.42 from $0.92. It also lowered FY2030 profit expectations to $3.41 from $3.73.
• Negative Sentiment: Insider selling adds a modest cautionary signal: David Malcom Rodman sold 2,170 shares worth approximately $58,785 under a pre-arranged Rule 10b5-1 plan, reducing his holdings by 4.05%. Insider sale disclosure

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.